Department of Urology, Athens University Medical School, LAIKO Hospital, Athens, Greece.
Int Braz J Urol. 2010 Jan-Feb;36(1):86-94. doi: 10.1590/s1677-55382010000100013.
To determine whether alpha1-blocker treatment, in chronic bladder outlet obstruction (BOO), influences bladder tissue ischemia.
This prospective study included 60 patients with BOO, of which 40 were under alpha1-blocker medication and 20 without treatment. Patients underwent transurethral resection of the prostate (TURP) or suprapubic prostatectomy (SPP). Ten patients with non-muscle invasive bladder cancer underwent transurethral resection of the bladder tumor and served as the control group. Tissue specimens were immunohistochemically stained for hypoxia inducible factor-1alpha (HIF-1alpha).
Bladder tissue from obstructed subjects showed high immunoreactivity to HIF-1alpha. The specimens from the control group, showed no or weak, mainly cytoplasmic immunoreactivity to HIF-1alpha. Patients under alpha -blocker treatment did not differ in the number of HIF-1alpha positive cells compared to subjects with no treatment (median number 86.8 [20-150] and 88.6 [0-175], respectively) (p > 0.05). The lowest bladder pressure at which HIF-1alpha was up regulated, was detected at detrusor pressure Qmax (PdetQmax) = 60 cm H2O.
Treatment with alpha-blockers in obstructed patients considered as non-responders, does not result in HIF-1alpha down regulation, thus bladder continues to be under chronic stress.
确定在慢性膀胱出口梗阻(BOO)中,α1 受体阻滞剂治疗是否会影响膀胱组织缺血。
本前瞻性研究纳入了 60 例 BOO 患者,其中 40 例接受 α1 受体阻滞剂治疗,20 例未接受治疗。患者接受经尿道前列腺切除术(TURP)或耻骨上前列腺切除术(SPP)。10 例非肌肉浸润性膀胱癌患者接受经尿道膀胱肿瘤切除术作为对照组。组织标本行缺氧诱导因子-1α(HIF-1α)免疫组织化学染色。
梗阻患者的膀胱组织显示出高 HIF-1α 免疫反应性。对照组标本 HIF-1α 阳性细胞数量较少或较弱,主要为细胞质免疫反应性。与未接受治疗的患者相比,接受 α 受体阻滞剂治疗的患者 HIF-1α 阳性细胞数量无差异(中位数分别为 86.8 [20-150] 和 88.6 [0-175])(p > 0.05)。在逼尿肌压力 Qmax(PdetQmax)=60cmH2O 时,检测到 HIF-1α 上调的最低膀胱压力。
在被认为是无反应者的梗阻患者中使用 α 受体阻滞剂治疗,不会导致 HIF-1α 下调,因此膀胱仍处于慢性应激状态。